For instance, the benefit of treatment with rituximab, a B cell depletion therapy, has been established for the treatment of refractory AChR‐Ab+ gMG and muscle‐specific tyrosine kinase (MuSK)‐MG in several studies.23, 24, 25, 26, 27, 28. This evidence concerns the gene MUSK and myasthenia gravis.